Trial Profile
A Phase 1b/2a, Two-Part, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects With Advanced Hematological Malignancies and Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 02 Jan 2019
Price :
$35
*
At a glance
- Drugs PLX 51107 (Primary)
- Indications Acute myeloid leukaemia; Breast cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Prostate cancer; Sarcoma; Solid tumours; Uveal melanoma
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Plexxikon
- 20 Dec 2018 Status changed from recruiting to discontinued.
- 05 Jul 2018 Planned End Date changed from 1 Mar 2018 to 1 May 2019.
- 05 Jul 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.